Indeed, EFTUD2 is also identified as a candidate cancer driver by the NCG database and recent evidence pointed at an oncogenic role for EFTUD2 in both BC [74] and CRC [75] but also in HCC [76], again strengthening the idea that our approach is a valid method to predict cancer-related genes, and underlining the importance also of interactor hubs. Here, EFTUD2 is linked to breast cancer.